On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.

On the news front, the domestic ADC sector has achieved concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving market approval, highlighting the leading advantage of Chinese companies. Additionally, the company's A-share IPO application for the SSE STAR Market has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug R&D, significantly boosting capital market attention.

At the industry level, the biotech sector rallied broadly, with 3SBIO up 10.72%, Akeso up 8.74%, Kelun-Biotech up 8.44%, and Innovent Biologics up 8.04%, reflecting strong sector-wide momentum. The company has also been actively conducting share buybacks and its founder previously announced plans to increase holdings, reinforcing confidence in intrinsic value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)